最新临床试验：培溴利珠单抗和达沙替尼、甲磺酸伊马替尼或尼罗替尼治疗慢性粒细胞白血病和持续可检测的微小残留病

这是经美国国家癌症研究所批准的一项多中心随机对照II期临床试验，目的是研究培溴珠单抗和达沙替尼、甲磺酸伊马替尼或尼罗替尼在治疗慢性粒细胞白血病和持续检测微小残留疾病（定义为血液中BCR-ABL基因产物水平）方面的作用。单克隆抗体的免疫治疗，如彭布罗珠单抗，可能有助于人体免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散能力。达沙替尼、甲磺酸伊马替尼和尼罗替尼可能通过阻断细胞生长所需的某些酶而阻止癌细胞的生长。给予培溴利珠单抗和达沙替尼、甲磺酸伊马替尼或尼罗替尼治疗慢性粒细胞白血病可能效果更好。

该临床试验正在全美198家医院进行开展。

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.